Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases

Patent metadata

Field	Value
Publication number	US-11419861-B2
Application number	US-202016852360-A
Country	US
Kind code	B2
Filing date	Apr 17, 2020
Priority date	Jun 27, 2014
Publication date	Aug 23, 2022
Grant date	Aug 23, 2022

Abstract

Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.

First claim

What is claimed is:

1. A method of identifying a test compound that induces a cereblon (CRBN) conformational change or an alteration of properties of a CRBN surface, wherein the method comprises:
(a) obtaining a first three-dimensional structure of CRBN and a reference compound;
(b) obtaining a second three-dimensional structure of CRBN and the test compound; and
(c) employing on a computer, the structural coordinates from the first set of atomic coordinates and the second set of atomic coordinates and comparing the two sets with one another, wherein identification of a test compound that induces a conformational change or alteration of properties of a CRBN surface is made by identifying a shift in the protein backbone or sidechains in the second set of atomic coordinates as compared to the first set atomic coordinates;
wherein a difference in the first and second three-dimensional structures is indicative of a test compound that induces the CRBN conformational change or alteration of properties of a CRBN surface;
wherein the CRBN conformational change or the alteration of properties of the CRBN surface occurs in a cereblon modifying agent (CMA) binding pocket of the CRBN and said change has an effect on amino acids corresponding to human CRBN W380, W386 and/or W400 of CRBN; has an effect on E377 of CRBN; or has an effect on V388 of CRBN, or within an adjacent region thereof; and
wherein the three-dimensional structures are determined by x-ray crystallography, NMR spectroscopy, dual polarization interferometry, vibrational spectroscopy, or cryo-electron microscopy.

2. The method of claim 1 , further comprising assessing whether or not said test compound has a specific downstream biological activity in a subject comprising administering the test compound to said subject wherein when a specific downstream biological activity is modulated in the subject it is indicative the test compound of having a specific downstream biological activity, and optionally, wherein said subject is a patient having a disease, and one or more symptoms of the disease are alleviated following administration of the test compound.

3. The method of claim 1 , assessing whether or not said test compound has a specific therapeutic efficacy by administering the test compound to a subject having a disease, disorder or condition, wherein one or more symptoms of the disease, disorder or condition are alleviated following administration of the test compound is indicative that said test compound has a specific therapeutic efficacy.

4. The method of claim 1 , wherein the CRBN of the first or second three-dimensional structure is further bound to DDB1, Cul4, Roc1, or any combination thereof.

5. The method of claim 1 , wherein the CRBN of the first or second three-dimensional structure is further bound to DDB1.

6. The method of claim 1 , wherein the CRBN three-dimensional structures are determined by x-ray crystallography.

7. The method of claim 1 , wherein the CRBN of the first or second three-dimensional structure is human CRBN or murine CRBN.

Assignees

• Celgene Corp

Inventors

• Chamberlain Philip
• Cathers Brian E
• Lopez-Girona Antonia

Classifications

• C12Q1/37

  involving peptidase or proteinase · CPC title

• G16B15/00

  ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/454 Primary

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title

• G16B15/30

  Drug targeting using structural data; Docking or binding prediction · CPC title